Mitigating Resistance & Virulence in MRSA

减轻阻力

• 批准号: 9238643
• 负责人: Michael R Yeaman
• 金额: $ 39.41万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-03-05 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9238643
• 关键词: Acetates; Address; Animal Model; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-inflammatory; Antibiotic Resistance; Antibiotics; Antimicrobial Resistance; Bacteria; Binding; Biological Assay; Bypass; Catheters; Clinical; Clinical Research; Clinical Treatment; Combined Antibiotics; Community Healthcare; Daptomycin; Data; Development; Devices; Diflunisal; Disease; Drug Design; FDA approved; Face; Failure; Fibronectins; Gene Expression; Gene Targeting; Genes; Genetic; Genome; Genotype; Goals; Growth; Halogens; Healthcare; Housekeeping; Housekeeping Gene; Human; In Vitro; Industry; Infection; Infectious Skin Diseases; Instinct; Intellectual Property; Investments; Kinetics; Knowledge; Lead; Life; Measurable; Measures; Mediating; Methicillin Resistance; Methods; Microbe; Microbial Biofilms; Modeling; Multi-Drug Resistance; Outcome; Pathogenicity; Peptides; Pharmaceutical Preparations; Phenotype; Populations at Risk; Positioning Attribute; Production; Proteins; Public Health; Resistance; Science; Skin; Specificity; Staphylococcus aureus; Structure; Time; Translating; Treatment Failure; Treatment outcome; United States National Institutes of Health; Validation; Vancomycin Resistance; Vancomycin-resistant S. aureus; Virulence; Virulence Factors; Work; analog; attributable mortality; clinical development; commercialization; community setting; cost; design; experience; hydroxybenzoate; improved; in vivo; innovation; killings; knowledge base; methicillin resistant Staphylococcus aureus; microbial; microbicide; multi-drug resistant pathogen; next generation; novel; pathogen; pre-clinical; prevent; programs; public health priorities; public health relevance; research and development; response; screening; small molecule libraries; soft tissue

DESCRIPTION (provided by applicant): Antibiotic resistance is a result of intrinsic or adaptive genotypic and phenotypic responses of microbes that face compounds designed to be microbicidal. This problem is highly significant for the priority pathogen, methicillin-resistant Staphylococcus aureus (MRSA), which has emerged in healthcare as well as community settings. To meet this challenge, we are taking an innovative direction: discover and/or develop antibiotics that modulate microbes rather than kill them. Through innovative strategies and methods, and use of well-defined, quantifiable milestones our project leverages our exciting discovery that diflunisal (DIF) and phenyl-hydroxybenzoate (POHB) analogues thereof mitigate genotypic and phenotypic antibiotic resistance and virulence in MRSA. In turn, this effect enhances antibiotic efficacy in vitro and in vivo. Our Preliminary Data have already revealed potential virulence, resistance, and regulatory target genes modulated by these compounds. Importantly, compounds emerging as leads from our preliminary data are known via extensive clinical experience to be safe and well-tolerated in humans, and are FDA-approved. Moreover, we have already established an intellectual property position with respect to new and repurposed anti-MRSA uses of these compounds, a key to accelerating clinical development and commercialization. Our assay validation platform and program is knowledge-based and data-driven, thereby having a distinct advantage over more random and unfocused high throughput chemical library screens. Integration of an in vivo screen component will validate efficacy in the most prevalent (skin / soft tissue) and most difficult-to-treat (device-related) foms of MRSA infection. We will focus our initial program on MRSA as a "proof-of-concept" pathogen. However, our assay platform and concepts should be readily adaptable to target other MDR pathogens beyond the scope of this application. Thus, our plan drives innovative science, assay optimization and target validation, and efficient milestone-driven progress to identify lead candidates that restore or enhance efficacy of existing antibiotics, while mitigating emergence of resistance. Ultimately, results from this project are intended to accelerate pre-clinical and clinial studies of antibiotic-POHB combinations to improve treatment outcomes in life-threatening MRSA infections in humans. This strategy is highly attractive and immediately applies to a significant public health issue, affording a realistic bridge to the prohibitive time and cost of discovery and development of entirely new antibiotics de novo.

描述（由申请人提供）：抗生素耐药性是微生物面对设计用于杀微生物的化合物时固有或适应性基因型和表型反应的结果。这个问题对于优先病原体，耐甲氧西林金黄色葡萄球菌（MRSA）非常重要，它已经出现在医疗保健和社区环境中。为了应对这一挑战，我们正在采取创新的方向：发现和/或开发调节微生物而不是杀死它们的抗生素。通过创新的策略和方法，以及使用明确定义的、可量化的里程碑，我们的项目利用了我们令人兴奋的发现，即二氟尼柳（DIF）及其苯羟基苯甲酸酯（POHB）类似物减轻了MRSA的基因型和表型抗生素耐药性和毒力。反过来，这种作用增强了体外和体内的抗生素功效。我们的初步数据已经揭示了这些化合物调节的潜在毒力，抗性和调控靶基因。重要的是，从我们的初步数据中作为先导化合物出现的化合物通过广泛的临床经验已知在人类中是安全和耐受性良好的，并且是FDA批准的。此外，我们已经建立了关于这些化合物的新的和重新利用的抗MRSA用途的知识产权地位，这是加速临床开发和商业化的关键。我们的分析验证平台和程序是基于知识和数据驱动的，因此与更随机和不集中的高通量化学库筛选相比具有明显的优势。体内筛选组件的整合将验证MRSA感染最常见（皮肤/软组织）和最难治疗（器械相关）形式的有效性。我们将把我们的初步计划集中在MRSA作为一种“概念验证”病原体上。然而，我们的测定平台和概念应易于适应于靶向超出本申请范围的其他MDR病原体。因此，我们的计划推动了创新科学、分析优化和靶标验证，以及有效的里程碑式进展，以确定恢复或增强现有抗生素疗效的主要候选药物，同时减少耐药性的出现。最终，该项目的结果旨在加速抗生素-POHB组合的临床前和临床研究，以改善人类危及生命的MRSA感染的治疗结果。这种策略非常有吸引力，并立即适用于一个重大的公共卫生问题，提供了一个现实的桥梁，禁止时间和成本的发现和开发全新的抗生素从头。